Literature DB >> 14407413

The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase.

A J JOHNSON, W R McCARTY.   

Abstract

Entities:  

Keywords:  STREPTODORNASE AND STREPTOKINASE/pharmacology; THROMBOSIS/experimental

Mesh：

Substances：

Year:  1959        PMID： 14407413      PMCID： PMC293294          DOI： 10.1172/JCI103941

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  30 in total

1.  The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients.

Authors:  W S TILLETT; A J JOHNSON; W R McCARTY
Journal:  J Clin Invest       Date:  1955-02       Impact factor: 14.808

2.  The enzymatic dissolution of experimental arterial thrombi in the dog by trypsin, chymotrypsin and plasminogen activators.

Authors:  S SHERRY; A TITCHENER; L GOTTESMAN; P WASSERMAN; W TROLL
Journal:  J Clin Invest       Date:  1954-10       Impact factor: 14.808

3.  The fibrinolytic activity of streptokinase activated human plasmin.

Authors:  S SHERRY
Journal:  J Clin Invest       Date:  1954-07       Impact factor: 14.808

4.  Lysis of thrombi produced by sodium morrhuate in the femoral vein of dogs by human plasmin (fibrinolysin).

Authors:  E E CLIFFTON; C E GROSSI; D CANNAMELA
Journal:  Ann Surg       Date:  1954-01       Impact factor: 12.969

5.  The action of plasmin on fibrin and fibrinogen in blood.

Authors:  S MULLERTZ
Journal:  Acta Physiol Scand       Date:  1953-03-31

6.  An activator system in blood indispensable for formation of plasmin by streptokinase.

Authors:  S MULLERTZ; M LASSEN
Journal:  Proc Soc Exp Biol Med       Date:  1953-02

7.  Studies on a proteolytic enzyme in human plasma. IX. Fibrinogen and fibrin as substrates for the proteolytic enzyme of plasma.

Authors:  O D RATNOFF
Journal:  J Clin Invest       Date:  1953-06       Impact factor: 14.808

8.  Involvement of a complement-like factor in the activation of blood protease.

Authors:  W B GEIGER
Journal:  J Immunol       Date:  1952-12       Impact factor: 5.422

9.  The inactivation of complement and its components by plasmin.

Authors:  L PILLEMER; O D RATNOFF; L BLUM; I H LEPOW
Journal:  J Exp Med       Date:  1953-04       Impact factor: 14.307
View more
  36 in total

1.  THE LABORATORY CONTROL OF THROMBOLYTIC THERAPY.

Authors:  C HAWKEY; M HOWELL
Journal:  J Clin Pathol       Date:  1964-05       Impact factor: 3.411

2.  THROMBOLYTIC THERAPY.

Authors:  A S DOUGLAS; G P MCNICOL
Journal:  Proc R Soc Med       Date:  1964-07

3.  ARTERIAL OCCLUSION TREATED WITH STREPTOKINASE. A REPORT OF TWO CASES.

Authors:  M L CLARK; M HOWELL; C HAWKEY; R S REES; J STUBBS
Journal:  Postgrad Med J       Date:  1965-02       Impact factor: 2.401

4.  STUDIES WITH COMPLAMIN, A NICOTINIC-ACID-THEOPHYLLINE ESTER, AS A FIBRINOLYTIC AGENT.

Authors:  G P MCNICOL; A S DOUGLAS
Journal:  Br Med J       Date:  1965-05-01

5.  Treatment of peripheral arterial occlusion by streptokinase perfusion.

Authors:  G P MCNICOL; W REID; W H BAIN; A S DOUGLAS
Journal:  Br Med J       Date:  1963-06-08

6.  Thrombolytic therapy.

Authors:  G P MCNICOL
Journal:  Proc R Soc Med       Date:  1963-05

7.  Feasibility of adequate thrombolytic therapy with streptokinase in peripheral arterial occlusions. I. Clinical and arteriographic results.

Authors:  M VERSTRAETE; A AMERY; J VERMYLEN
Journal:  Br Med J       Date:  1963-06-08

8.  Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization.

Authors:  N ALKJAERSIG; A P FLETCHER; S SHERRY
Journal:  J Clin Invest       Date:  1962-04       Impact factor: 14.808

9.  Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products.

Authors:  A P FLETCHER; N ALKJAERSIG; S SHERRY
Journal:  J Clin Invest       Date:  1962-04       Impact factor: 14.808

10.  [Lysis of human blood clots in vitro].

Authors:  H ROSOLLECK
Journal:  Klin Wochenschr       Date:  1961-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.